Treatment of chronic viral hepatitis C in the female patient with mucinous adenocarcinoma of the pancreas
Viktorijo Borisovna Poluektova , Elena Vasil’evna Volchkova , Pavel Igorevic Davydenko , Ekaterina Mihaylovna Fillipova
Epidemiology and Infectious Diseases ›› 2014, Vol. 19 ›› Issue (6) : 4 -10.
Treatment of chronic viral hepatitis C in the female patient with mucinous adenocarcinoma of the pancreas
When planning the antiviral therapy (AVT) in patients with chronic gastrointestinal diseases in a history, a number ofadditional factors should be taken into account. In particular, at the start of the AVT it can be possible the activation of hidden malignancy occurring before. At the same time, the management of such patients at the background of the start of AVT in HCV cases has not practically developed. We have seen the female HCV patient with the cyst of the pancreas. Antiviral therapy has triggered the development of the abdominal pain syndrome. Additional tests: CT, endoultrasound, MRT of the abdomen revealed a colloidal adenocarcinoma of the tail of the pancreas. Removal of the tumour, 6 courses of chemotherapy and the absence of its relapses allowed to start and successfully carry out the AVT for HCV. The taken tactics of the patient and the used drugs well constrained the process of the reactivation of the tumour of the pancreas during therapy and for 4 months after the its accomplishment.
antiviral therapy (AVT) / pancreatic cyst (cyst of the pancreas) / adenocarcinoma of the pancreas
| [1] |
Miyake Y., Iwasaki Y., Yamamoto K. Meta-analysis: reduced incidence of hepatocellular carcinoma in patients not responding to interferon therapy of chronic hepatitis C. Int. J. Cancer. 2010; 127(4): 989-96. |
| [2] |
Sarrazin C., Hezode C., Zeuzem S., Pawlotsky J.-M. Стратегии противовирусной терапии хронического гепатита С. Клиническая гепатология. 2012; 8(2): 20-31. |
| [3] |
Сюткин В.Е. Противовирусная терапия хронического гепатита С: вчера, сегодня, завтра, послезавтра. Инфекционные болезни. 2013; 11(1): 61-70. |
| [4] |
Kiser J.J., Burton J.R.Jr., Everson G.T. Drug-drug interaction during antiviral therapy for chronic hepatitis. Nat. Rev. Gastroenterol. Hepatol. 2013; 10(10): 596-606. |
| [5] |
Flisiak R., Jaroszewicz J., Parfieniuk-Kowerda A. Emerging treatments for hepatitis C. Expert. Opin. Emerg. Drugs. 2013; 18(4): 461-75. |
| [6] |
Ghany M.G., Nelson D.R., Strader D.B. et al. Genotype 1 HCV treatment guidelines. Hepatology. 2011; 54: 1433-44. |
| [7] |
Хайрулин Т.Р., Гармаш И.В., Малая И.П., Виллевальде С.В. Клинико-эпидемиологическая характеристика и распространенность НСV-инфекции у больных общесоматического стационара. Клиническая гепатология. 2012; 8(2): 9-13. |
| [8] |
Гришанков С.А., Кубышкин В.А., Кармазановский Г.Г. Кистозные опухоли поджелудочной железы. Хирургия. 2006;11. |
| [9] |
Sarr M.G., Murr M., Smyrk T.C. et al. Primary cystic neoplasms of the pancreas: neoplastic disorders of emerging importance: current state of the art and unanswered questions. J. Gastrointest. Surg. 2003; 7: 417-28. |
| [10] |
Thompson L.D., Becker R.C., Przygodzki R.M. et al. Mucinous cystic neoplasm (mucinous cystadenocarcinoma of low-grade malignant potential) of the pancreas: a clinicopathologic study of 130 cases. Am. J. Surg. Pathol. l999; 23: 1-16. |
| [11] |
Zamboni G., Scarpa A., Bogina G. et al. Mucinous cystic tumors of the pancreas: clinicopathological features, prognosis, and relationship to other mucinous cystic tumors. Am. J. Surg. Pathol. l999; 23: 410-22. |
| [12] |
Козлов К.В. Патогенетическая характеристика метаболизма железа у больных хроническим гепатитом С: Дис.. канд. мед. наук; 2009. |
Eco-vector
/
| 〈 |
|
〉 |
PDF
